SCHEMBL16611138

SCHEMBL16611138

Cc1ccccc1-n1nc(-c2ccc(S(N)(=O)=O)cc2)c2c(=O)[nH]ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.47
CA2 P00918 6/20 0.47
CA4 P22748 2/20 0.47
CA7 P43166 2/20 0.47
PTGS2 P35354 10/20 0.43
PTGS1 P23219 5/20 0.43
CA12 O43570 4/20 0.40
CA9 Q16790 4/20 0.40
IKBKB O14920 2/20 0.38
CHUK O15111 2/20 0.38
MT-CO2 P00403 1/20 0.37
LMNA P02545 1/20 0.37
CA3 P07451 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
CYP3A4 P08684 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
ADRA2B P18089 1/20 0.37
CA6 P23280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611037 0.87 PTGS1 (0.44) CA1CA2CA4CA7PTGS2
SCHEMBL16611328 0.87 PTGS1 (0.43) CA1CA2CA4CA7PTGS2
SCHEMBL16610815 0.85 PDPK1 (0.39) CA1CA2PTGS2PTGS1IKBKB
SCHEMBL16726687 0.84 GSK3B (0.34) LMNAADORA3PDE4A
SCHEMBL16610763 0.84 CA1 (0.44) CA1CA2CA4CA7PTGS2
SCHEMBL18052616 0.84 ALDH1A1 (0.34)
SCHEMBL16611040 0.80 PTGS1 (0.40) CA1CA2PTGS2PTGS1CA12
SCHEMBL16610690 0.77 CHUK (0.41) CA1CA2PTGS2PTGS1CA12
SCHEMBL16610934 0.76 CA1 (0.40) CA1CA2PTGS2PTGS1CA12
SCHEMBL16610875 0.73 JAK2 (0.52) PTGS2IKBKBCHUKJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 CA1 2704/4885CA2 1618/4885CA4 1954/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 CA1 2704/4885CA2 1618/4885CA4 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.